MA31202B1 - Procede de traitement du cancer - Google Patents

Procede de traitement du cancer

Info

Publication number
MA31202B1
MA31202B1 MA32188A MA32188A MA31202B1 MA 31202 B1 MA31202 B1 MA 31202B1 MA 32188 A MA32188 A MA 32188A MA 32188 A MA32188 A MA 32188A MA 31202 B1 MA31202 B1 MA 31202B1
Authority
MA
Morocco
Prior art keywords
way
treat cancer
mammal
human
effective amount
Prior art date
Application number
MA32188A
Other languages
Arabic (ar)
English (en)
Inventor
Connie Lynn Erickson-Miller
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31202(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA31202B1 publication Critical patent/MA31202B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé de traitement du cancer et des syndromes précancéreux chez un mammifère, y compris chez un être humain en ayant besoin, qui comprend l'administration d'une quantité thérapeutiquement efficace d'un agoniste de récepteur de tpo non-peptidique à un tel mammifère.
MA32188A 2007-02-16 2009-08-31 Procede de traitement du cancer MA31202B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US89255207P 2007-03-02 2007-03-02
US90820507P 2007-03-27 2007-03-27
US94934707P 2007-07-12 2007-07-12
US95228907P 2007-07-27 2007-07-27
US96919207P 2007-08-31 2007-08-31
US97721607P 2007-10-03 2007-10-03
PCT/US2008/054046 WO2008101141A2 (fr) 2007-02-16 2008-02-15 Procédé de traitement du cancer

Publications (1)

Publication Number Publication Date
MA31202B1 true MA31202B1 (fr) 2010-02-01

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32188A MA31202B1 (fr) 2007-02-16 2009-08-31 Procede de traitement du cancer

Country Status (28)

Country Link
US (2) US20100075928A1 (fr)
EP (1) EP2124547B3 (fr)
JP (1) JP5511391B2 (fr)
KR (1) KR101447763B1 (fr)
CN (1) CN101662937B (fr)
AR (1) AR065348A1 (fr)
AU (1) AU2008216106C1 (fr)
BR (1) BRPI0807940B8 (fr)
CA (1) CA2678358C (fr)
CR (1) CR10997A (fr)
DK (1) DK2124547T6 (fr)
EA (1) EA017715B1 (fr)
ES (1) ES2675070T7 (fr)
FI (1) FI2124547T4 (fr)
HU (1) HUE038563T2 (fr)
IL (2) IL200319A (fr)
MA (1) MA31202B1 (fr)
MX (1) MX2009008822A (fr)
NZ (1) NZ579068A (fr)
PE (1) PE20081784A1 (fr)
PL (1) PL2124547T6 (fr)
PT (1) PT2124547T (fr)
SI (1) SI2124547T2 (fr)
TR (1) TR201809010T4 (fr)
TW (1) TW200906393A (fr)
UY (1) UY30915A1 (fr)
WO (1) WO2008101141A2 (fr)
ZA (1) ZA200905532B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
KR101530402B1 (ko) * 2007-10-09 2015-06-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (tpora)
EP2434894B1 (fr) 2009-05-29 2016-08-31 Novartis AG Procédés d'administration de composés agonistes de la thrombopoïétine
CA2808908A1 (fr) * 2010-09-01 2012-03-08 Novartis Ag Association d'inhibiteurs de hdac et de medicaments contre la thrombopenie
WO2014150252A1 (fr) * 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Méthodes de traitement associées au récepteur du facteur de stimulation des colonies de granulocytes
SMT202300047T1 (it) * 2016-05-06 2023-03-17 Taris Biomedical Llc Metodo di trattamento del cancro uroteliale del tratto inferiore
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска
CN121588107A (zh) * 2024-08-26 2026-03-03 李欣蕊 阿伐曲泊帕及其新治疗用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (fr) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Ligands du recepteur mpl, leur procede de preparation, medicaments les contenant et leur utilisation pour le traitement et la prevention de la thrombocytopenie et l'anemie
KR20020069183A (ko) * 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
DE60043156D1 (de) * 1999-11-10 2009-11-26 Biopheresis Technologies Inc Verfahren und system zur entfernung von zytokininhibitoren in patienten
EP1104674A1 (fr) 1999-11-10 2001-06-06 Curacyte AG Colorants o-o'-dihydroxy azoiques dans des médicaments ayant une activité TPO-agoniste ou synergétique
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
TWI282785B (en) * 2000-05-30 2007-06-21 Chugai Pharmaceutical Co Ltd A compound having thrombopoietin-like activities
EP1284997B1 (fr) * 2000-05-31 2005-04-06 Genzyme Corporation Composes therapeutiques contre le cancer des ovaires
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
MXPA03006510A (es) 2001-01-26 2003-10-15 Shionogi & Co Compuestos halogenados que muestran agonismo del receptor de trombopoyetina.
WO2002059099A1 (fr) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine
JPWO2002062775A1 (ja) * 2001-02-02 2004-06-10 山之内製薬株式会社 2−アシルアミノチアゾール誘導体又はその塩
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
CN101062053A (zh) * 2001-09-24 2007-10-31 托斯克公司 减低毒性的顺铂制剂及其使用方法
PT1466912E (pt) 2002-01-18 2013-06-28 Astellas Pharma Inc Derivado de 2-aciloaminotiazol ou seu sal
MY142390A (en) * 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2004029049A1 (fr) 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. Nouveau sel d'un derive de 2-acylaminothiazole
EP1622609A4 (fr) * 2003-04-29 2008-09-03 Smithkline Beecham Corp Procedes de traitement de maladies/lesions degeneratives
WO2005118551A2 (fr) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Composes modulant l'activite de la thrombopoietine et methodes associees
DE602005024599D1 (de) * 2004-10-25 2010-12-16 Ligand Pharm Inc Verbindungen modulierende thrombopoietinaktivität und verfahren
CA2630234A1 (fr) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Composes modulant l'activite thrombopoietine et procedes correspondants
MX2008011666A (es) 2006-03-15 2008-10-17 Ligand Pharm Inc Sintesis de compuestos que modulan la actividad de la trombopoyetina.

Also Published As

Publication number Publication date
SI2124547T2 (sl) 2025-07-31
DK2124547T6 (da) 2025-09-01
ZA200905532B (en) 2010-04-28
IL200319A (en) 2015-05-31
BRPI0807940B1 (pt) 2020-10-27
CA2678358A1 (fr) 2008-08-21
JP2010519221A (ja) 2010-06-03
US20100075928A1 (en) 2010-03-25
PL2124547T3 (pl) 2018-08-31
WO2008101141A3 (fr) 2008-10-16
AU2008216106B2 (en) 2013-07-11
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
IL200319A0 (en) 2010-04-29
EP2124547B2 (fr) 2025-04-16
EA200970776A1 (ru) 2010-02-26
EP2124547A4 (fr) 2010-05-05
EA017715B1 (ru) 2013-02-28
TW200906393A (en) 2009-02-16
AU2008216106A1 (en) 2008-08-21
EP2124547A2 (fr) 2009-12-02
PL2124547T5 (pl) 2025-08-04
EP2124547B1 (fr) 2018-03-28
KR101447763B1 (ko) 2014-10-07
CN101662937A (zh) 2010-03-03
BRPI0807940B8 (pt) 2021-05-25
IL238394B (en) 2018-05-31
DK2124547T3 (en) 2018-07-16
PL2124547T6 (pl) 2026-06-01
IL238394A0 (en) 2015-06-30
PE20081784A1 (es) 2009-01-25
ES2675070T7 (en) 2025-08-06
FI2124547T4 (fi) 2025-07-29
CR10997A (es) 2009-10-16
CA2678358C (fr) 2015-12-08
SI2124547T1 (en) 2018-08-31
TR201809010T4 (tr) 2018-07-23
BRPI0807940A2 (pt) 2013-07-30
AU2008216106C1 (en) 2025-11-13
NZ579068A (en) 2012-05-25
DK2124547T4 (da) 2025-08-04
PT2124547T (pt) 2018-07-04
UY30915A1 (es) 2008-09-02
HUE038563T2 (hu) 2018-10-29
WO2008101141A2 (fr) 2008-08-21
AR065348A1 (es) 2009-06-03
CN101662937B (zh) 2014-03-12
ES2675070T3 (es) 2018-07-06
EP2124547B3 (fr) 2025-06-18
AU2008216106B9 (en) 2013-09-05
MX2009008822A (es) 2009-08-28
JP5511391B2 (ja) 2014-06-04

Similar Documents

Publication Publication Date Title
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
EA201690111A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
EP2103628A4 (fr) Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d&#39;un tel anticorps
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
UA102667C2 (uk) Людське нейтралізуюче антитіло проти в7rp1
WO2007087151A3 (fr) Méthode de traitement d&#39;un dysfonctionnement cognitif
CR10297A (es) &#34;metodos para prevenir y tratar efermedades amiloidogenicas&#34;
MA32056B1 (fr) Suspension pharmaceutique orale contenant du paracetamol et de l&#39;ibuprofene
MX360150B (es) Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos.
EP2001510A4 (fr) Procédés de traitement du lupus au moyen d&#39;anticorps cd4
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
EP2029164A4 (fr) Thérapie de recrutement anti-leucocytaire pour le traitement de crises épileptiques et de l&#39;épilepsie
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA32684B1 (fr) Dérivés de picolinamide en tant qu&#39;inhibiteurs de kinase
EP2307032A4 (fr) Nouveaux conjugués de polymères sur lesquels sont fixés un agent thérapeutiquement actif et une fraction ciblant l&#39;angiogenèse et utilisations de ces conjugués pour traiter des maladies liées à l&#39;angiogenèse
EP2367561A4 (fr) Compositions et procédés pour le traitement d&#39;une maladie coeliaque
MA33724B1 (fr) Anticorps neutralisants anti-ngf humain en tant qu&#39;inhibiteurs selectifs de la voie du ngf
EP2047863A4 (fr) Prévention ou traitement d&#39;une maladie inflammatoire
EP2320904A4 (fr) Inhibiteurs aminopyrimidine des récepteurs de l&#39;histamine destinés au traitement d&#39;une maladie
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
MX2009008822A (es) Metodo de tratamiento de canceres.
EP2498774A4 (fr) Composés à double action ciblant le récepteur d&#39;adénosine a2a et un transporteur d&#39;adénosine pour la prévention et le traitement de maladies neurodégénératives
ECSP099308A (es) Métodos de tratamiento de la depresión
MA31757B1 (fr) Traitement de symptomes vasomoteurs